Literature DB >> 2425731

PPi analogs as inhibitors of human T-lymphotropic virus type III reverse transcriptase.

L Vrang, B Oberg.   

Abstract

Twenty-six PPi analogs were tested for inhibitory effects on human T-lymphotropic virus type III reverse transcriptase. The structural requirements for inhibition and mechanism of action of the most active inhibitors have been investigated. Foscarnet (phosphonoformic acid) was the most potent inhibitor of human T-lymphotropic virus type III reverse transcriptase with 50% inhibition at 0.5 microM. The mechanism was a noncompetitive type of inhibition of a (riboadenylic acid)n . (deoxythymidylic acid)12-18 [(rA)n(dT)12-18]-directed transcription at varied dTTP concentration. At constant substrate (dTTP) concentration and varied amounts of template, (rA)n(dT)12-18, the inhibitory action of foscarnet was of an uncompetitive type. The same pattern of inhibition was seen when the less active inhibitor carbonyldiphosphonate was studied under identical conditions. The structural requirements for inhibition of human T-lymphotropic virus type III reverse transcriptase by PPi analogs were similar to those shown by other reverse transcriptases.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2425731      PMCID: PMC284169          DOI: 10.1128/AAC.29.5.867

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  11 in total

1.  Inhibition of HTLV-III/LAV replication by foscarnet.

Authors:  P S Sarin; Y Taguchi; D Sun; A Thornton; R C Gallo; B Oberg
Journal:  Biochem Pharmacol       Date:  1985-11-15       Impact factor: 5.858

2.  Inhibition of human T-cell lymphotropic virus type III in vitro by phosphonoformate.

Authors:  E G Sandstrom; J C Kaplan; R E Byington; M S Hirsch
Journal:  Lancet       Date:  1985-06-29       Impact factor: 79.321

3.  Observations on the suramin-mediated inhibition of cellular and viral DNA polymerases.

Authors:  A Basu; M J Modak
Journal:  Biochem Biophys Res Commun       Date:  1985-05-16       Impact factor: 3.575

4.  Suramin protection of T cells in vitro against infectivity and cytopathic effect of HTLV-III.

Authors:  H Mitsuya; M Popovic; R Yarchoan; S Matsushita; R C Gallo; S Broder
Journal:  Science       Date:  1984-10-12       Impact factor: 47.728

5.  Phosphonoformate inhibition of visna virus replication.

Authors:  B Sundquist; E Larner
Journal:  J Virol       Date:  1979-06       Impact factor: 5.103

6.  Phosphonoformate inhibits reverse transcriptase.

Authors:  B Sundquist; B Oberg
Journal:  J Gen Virol       Date:  1979-11       Impact factor: 3.891

7.  Sequence homology and morphologic similarity of HTLV-III and visna virus, a pathogenic lentivirus.

Authors:  M A Gonda; F Wong-Staal; R C Gallo; J E Clements; O Narayan; R V Gilden
Journal:  Science       Date:  1985-01-11       Impact factor: 47.728

8.  Inhibition of reverse transcriptase activity of avian myeloblastosis virus by pyrophosphate analogues.

Authors:  B Eriksson; G Stening; B Oberg
Journal:  Antiviral Res       Date:  1982-05       Impact factor: 5.970

9.  Pyrophosphate analogues as inhibitors of herpes simplex virus type 1 DNA polymerase.

Authors:  B Eriksson; A Larsson; E Helgstrand; N G Johansson; B Oberg
Journal:  Biochim Biophys Acta       Date:  1980-03-28

10.  Detection, isolation, and continuous production of cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS.

Authors:  M Popovic; M G Sarngadharan; E Read; R C Gallo
Journal:  Science       Date:  1984-05-04       Impact factor: 47.728

View more
  22 in total

1.  Inhibition of human immunodeficiency virus in vitro by combinations of 3'-azido-3'-deoxythymidine and foscarnet.

Authors:  R Koshida; L Vrang; G Gilljam; J Harmenberg; B Oberg; B Wahren
Journal:  Antimicrob Agents Chemother       Date:  1989-05       Impact factor: 5.191

Review 2.  Antiviral therapy in AIDS. Clinical pharmacological properties and therapeutic experience to date.

Authors:  E G Sandström; J C Kaplan
Journal:  Drugs       Date:  1987-09       Impact factor: 9.546

Review 3.  Antiviral therapy: current concepts and practices.

Authors:  B Bean
Journal:  Clin Microbiol Rev       Date:  1992-04       Impact factor: 26.132

4.  Azidothymidine triphosphate is an inhibitor of both human immunodeficiency virus type 1 reverse transcriptase and DNA polymerase gamma.

Authors:  H König; E Behr; J Löwer; R Kurth
Journal:  Antimicrob Agents Chemother       Date:  1989-12       Impact factor: 5.191

5.  Inhibition of human immunodeficiency virus reverse transcriptase by 2',3'-dideoxynucleoside triphosphates: template dependence, and combination with phosphonoformate.

Authors:  M C Starnes; Y C Cheng
Journal:  Virus Genes       Date:  1989-05       Impact factor: 2.332

6.  Visna virus as an in vitro model for human immunodeficiency virus and inhibition by ribavirin, phosphonoformate, and 2',3'-dideoxynucleosides.

Authors:  K B Frank; P A McKernan; R A Smith; D F Smee
Journal:  Antimicrob Agents Chemother       Date:  1987-09       Impact factor: 5.191

7.  Kinetics and inhibition of reverse transcriptase from human and simian immunodeficiency viruses.

Authors:  J C Wu; M Chernow; R E Boehme; R T Suttmann; M J McRoberts; E J Prisbe; T R Matthews; P A Marx; R Y Chuang; M S Chen
Journal:  Antimicrob Agents Chemother       Date:  1988-12       Impact factor: 5.191

Review 8.  Antiviral therapy in human immunodeficiency virus infections. Current status (Part II).

Authors:  E Sandström; B Oberg
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

9.  Conformational States of HIV-1 Reverse Transcriptase for Nucleotide Incorporation vs Pyrophosphorolysis-Binding of Foscarnet.

Authors:  Kalyan Das; Jan Balzarini; Matthew T Miller; Anita R Maguire; Jeffrey J DeStefano; Eddy Arnold
Journal:  ACS Chem Biol       Date:  2016-06-06       Impact factor: 5.100

10.  RNase H activity associated with reverse transcriptase from feline immunodeficiency virus.

Authors:  R C Cronn; J D Whitmer; T W North
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.